OrbiMed and WuXi Huiying Investment Lead USD40m Series C for Chinese Medical Technology Developer AnchorDx
Source(s): AnchorDx
OrbiMed and WuXi Huiying Investment led a USD40m Series C for AnchorDx, a China-based medical technology developer focused on DNA sequencing and diagnostics. Read more